Matt Murphy
Partner·Menlo Ventures
Bio
Professional summary
Matt Murphy is a Partner at Menlo Ventures focused on multi-stage investing across AI infrastructure and AI-native software. Menlo's profile lists focus areas including AI, SaaS, infrastructure, and robotics plus hardware, and describes his AI infrastructure interests as DevOps, data stack, middleware, and API platforms. Since joining Menlo in 2015, he has led or participated in investments including Anthropic, Alloy.ai, Benchling, Carta, Envoy, Harness, Hover, Netlify, Observable, OpenRouter, Relyance.ai, Semgrep, Skild, True Anomaly, Vivun, and Zylo. Before Menlo, he spent 15 years as a general partner at Kleiner Perkins, where he was involved with companies including Google, DocuSign, Upstart, AppDynamics, Puppet, Shazam, and others.
Investment focus
Stage, sector, and overall fit
Stage
Sector
Thesis
Notable companies
Selected portfolio companies the partner has backed
How to approach
Framing and angles for outreach
Pitch framing
Best angle is a technically differentiated AI infrastructure or AI-native software pitch with evidence of developer, enterprise, or platform adoption.
Partneralization hooks
- 1Deep history in infrastructure and developer/platform companies across both Menlo and Kleiner Perkins.
- 2Portfolio relevance if the company touches AI infrastructure, data, DevOps, or APIs.
Recent signals
What the partner has said or done recently
Menlo profile lists current AI infrastructure and AI-native software companies including OpenRouter, Semgrep, Skild, and True Anomaly.
Background
Career, education, and skills
Career history
- Menlo VenturesPartnerPresent
- Kleiner Perkins Caufield & ByersGeneral Partner~15 years prior
- NetboostOperating rolePrior; acquired by Intel
Education
- Stanford University Graduate School of BusinessM.B.A.
Skills
Other partners at Menlo Ventures
12 more profiles
Amy Wu Martin
Partner
Menlo Ventures
Amy Wu Martin is a Partner at Menlo Ventures focused on AI and consumer companies, with a background in consumer technology, gaming, blockchain, and digital media. She joined Menlo to grow its consumer technology and gaming practice.
C.C. Gong
Principal
Menlo Ventures
Menlo principal investing in consumer tech, SaaS, and AI applications.
Croom Beatty
Partner
Menlo Ventures
Croom Beatty is a Partner at Menlo Ventures focused on application-layer AI, fintech, healthcare IT, and vertical software. Since joining Menlo in 2017, he has led investments in companies including Arch, Finch, Manifest, NationGraph, Numeric, Prodigal, Rivet, Slash, Abacus, Accordance, Relcu, and Squad Health.
Deborah Carrillo
General Counsel, Partner
Menlo Ventures
General Counsel and Partner overseeing legal, fund, deal, and compliance work at Menlo.
Deedy Das
Partner
Menlo Ventures
Early-stage AI, infrastructure, and enterprise software investor; ex-Glean, Google, and Facebook.
Derek Xiao
Principal
Menlo Ventures
Menlo principal backing AI, cloud infrastructure, and digital health startups.
Doug Carlisle
Partner Emeritus
Menlo Ventures
Longtime Menlo IT investor behind Hotmail, IronPort, Ansible, nLight, and Synthego.
Greg Yap
Partner
Menlo Ventures
Greg Yap is a Partner at Menlo Ventures focused on life science, healthcare, and AI, with special interest in novel therapeutic platforms, digital health, and transformative technologies. Since joining Menlo in 2017, he has led investments including Cartwheel, Clear Labs, Curie, Delfi, Encoded, Genesis, H1, Ophelia, Particle, Pliant, Scribe, Vilya, and Xaira.
Houman Haghighi
Partner, Business & Corporate Development
Menlo Ventures
Business development partner helping Menlo portfolio companies scale through partnerships.
Ishika C.
Investor
Menlo Ventures
Menlo investor focused on AI/ML, SaaS, and cloud infrastructure.
Joff Redfern
Partner
Menlo Ventures
Joff Redfern is a partner at Menlo Ventures focused on software development workflows, AI-driven future-of-work products, and network-effect businesses including marketplaces.
Johnny Hu
Principal
Menlo Ventures
Menlo principal investing in biotech, life sciences, and novel therapeutics.